人才建設(shè)

您所在的位置: 首頁(yè) - 人才建設(shè) - 師資隊(duì)伍 - 準(zhǔn)聘長(zhǎng)聘教師 - 助理教授 - 醫(yī)藥生物技術(shù)研究所

醫(yī)藥生物技術(shù)研究所

  • 姓 名:

    李珂

  • 單 位:

    中國(guó)醫(yī)學(xué)科學(xué)院醫(yī)藥生物技術(shù)研究所

  • 教職崗位:

    助理教授

  • 聘任時(shí)間:

    2021-07-01

  • 一級(jí)學(xué)科:

    藥學(xué)

  • 二級(jí)學(xué)科:

    微生物與生化藥學(xué)(藥理學(xué)方向)

  • 聯(lián)系方式:

    [email protected]

  • 導(dǎo)師風(fēng)采鏈接:
    http://pumc.teacher.360eol.com/teacherBasic/preview?teacherId=4762

個(gè)人簡(jiǎn)介

李珂,1986年生,籍貫河南,腫瘤藥理學(xué)家,中國(guó)醫(yī)學(xué)科學(xué)院醫(yī)藥生物技術(shù)研究所研究員,博士生導(dǎo)師。2004年考入山東大學(xué)藥學(xué)專業(yè),2008年獲得學(xué)士學(xué)位。2008年在北京協(xié)和醫(yī)學(xué)院藥物研究所藥理學(xué)專業(yè)攻讀碩/博士學(xué)位,從事靶向Toll樣受體2抑制腫瘤及多肽類藥物的篩選研究。2013年進(jìn)入中國(guó)醫(yī)學(xué)科學(xué)院醫(yī)藥生物技術(shù)研究所工作,主要研究靶向異常蛋白質(zhì)降解系統(tǒng)清除腫瘤起始細(xì)胞。


主要研究方向

圍繞“靶向蛋白質(zhì)降解系統(tǒng)清除腫瘤起始細(xì)胞”的研究方向:篩選維持腫瘤起始細(xì)胞功能的特異性標(biāo)志分子或關(guān)鍵信號(hào)通路;解析維持腫瘤起始細(xì)胞功能的靶蛋白穩(wěn)定性調(diào)控機(jī)制;對(duì)藥靶蛋白進(jìn)行藥物設(shè)計(jì)和篩選。


代表性成果

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Li K#*, Zhang TT#, Zhao CX#, Wang F, Cui B, Yang ZN, Lv XX, Yeerjiang Z, Yuan YF, Yu JM, Wang ZH, Zhang XW, Yu JJ, Liu SS, Shang S, Huang B, Hua F*, Hu ZW*. Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability. Sci Transl Med 2021 Mar 24;13(586): eabb2914. (IF=19.351)


2. Li K#, Wang F#, Yang ZN, Zhang TT, Yuan YF, Zhao CX, Y Z, Cui B, Hua F, Lv XX, Zhang XW, Yu JJ, Liu SS, Yu JM, Shang S, Xiao Y, Hu ZW*. TRIB3 Promotes MYC-associated Lymphoma Development through Suppression of UBE3B-Mediated MYC Degradation. Nat Commun. 2020 11(1): 6316. IF=14.919


3. Li K#, Wang F#, Yang ZN#, Cui B, Li PP, Li ZY, Hu ZW*, Zhu HH*. PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020 Aug 15;10(22): 10326-10340. (IF=11.556)


4. Zhu HH#, Yang MC#, Wang F#, Lou YJ, Jin J, Li K*, Zhang SZ*. Identification of a novel NUP98-RARA fusion transcript as the 14th variant of acute promyelocytic leukemia. Am J Hematol. 2020 Jul;95(7): E184-E186. (IF=10.047)


5. Xue ST#, Li K#, Gao Y, Zhao LY, Gao Y, Yi H, Jiang JD*, and Li ZR*. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target. Autophagy, 2020 Jan 27: 1-15. (IF=16.016)


6. Li K, Zhang TT, Hu ZW*. Metformin Reduces TRIB3 Expression and Restores Autophagy Flux: An Alternative Antitumor Action. Autophagy. 2018 Jul 20: 1-2. (IF=11.059)


7. Li K, Zhang TT, Wang F, Cui B, Zhao CX, Yu JJ, Lv XX, Zhang XW, Yang ZN, Huang B, Li X, Hua F, Hu ZW*. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene. 2018 Jul 20: 1-2. (IF=6.854)


8. Li K#, Wang F#, Cao WB, Lv XX, Hua F, Cui B, Yu JJ, Zhang XW, Shang S, Liu SS, Yu JM, Han MZ, Huang B, Zhang TT, Li X, Jiang JD, Hu ZW*. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARa and Inhibition of p53-Mediated Senescence. Cancer Cell, 2017, 31: 697-710. (IF=22.844)


9. Hua F#, Li K#, Yu JJ#, Lv XX, Yan J, Zhang XW, Sun W, Lin H, Shang S, Wang F, Cui B, Mu R, Huang B, Jiang JD, Hu ZW*. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun. 2015, 13;6: 7951. (#contributing equally) (IF=11.329)


10. Li K#, Lv XX, Hua F, Lin H, Sun W, Cao WB, Fu XM, Xie J, Yu JJ, Li Z, Liu H, Han MZ and Hu ZW*. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Intl J Cancer. 2014; 134: 692-702. (IF=5.085)